Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002234 · ClinicalTrials.gov registry record · Phase 2
Safety and Effectiveness of Giving an Anti-HIV Drug Combination of Adefovir Dipivoxil Plus Didanosine Plus Efavirenz Plus Lamivudine Once Daily to HIV-Infected Patients
A Phase 2 study of HIV Infections, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 5
- Study locations
NCT00002234 is a Phase 2 study of HIV Infections that has completed, run by Gilead Sciences. The registered enrollment target is 25 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (94% lower). The trial reports 5 study locations across 5 states.
The verdict
NCT00002234, a Phase 2 study of HIV Infections, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to see if it is safe and effective to give HIV-infected patients a new combination of anti-HIV drugs taken once daily.
Conditions Studied
Interventions
- DRUG Lamivudine
- DRUG Efavirenz
- DRUG Didanosine
- DRUG Adefovir dipivoxil
Study Locations (5)
California
- Pacific Oaks Med Group - Beverly Hills
Colorado
- Univ of Colorado / Health Science Ctr - Denver
Georgia
- AIDS Research Consortium of Atlanta - Atlanta
Rhode Island
- Brown Univ School of Medicine - Providence
Virginia
- Hampton Roads Med Specialists - Hampton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002234
The ClinicalTrials.gov registry entry for NCT00002234 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (94% lower). The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 4 interventions - of which Lamivudine is the first listed.
NCT00002234 reports 5 study locations spanning 5 distinct geographic areas - top geographies include California, Colorado, Georgia.
Frequently Asked Questions
What is clinical trial NCT00002234 about?
NCT00002234 is a clinical study titled "Safety and Effectiveness of Giving an Anti-HIV Drug Combination of Adefovir Dipivoxil Plus Didanosine Plus Efavirenz Plus Lamivudine Once Daily to HIV-Infected Patients". The purpose of this study is to see if it is safe and effective to give HIV-infected patients a new combination of anti-HIV drugs taken once daily.
What is the current status of trial NCT00002234?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants.
What conditions does trial NCT00002234 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00002234?
The interventions under investigation include: Lamivudine (DRUG), Efavirenz (DRUG), Didanosine (DRUG), Adefovir dipivoxil (DRUG).
Who is sponsoring clinical trial NCT00002234?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00002234 being conducted?
This trial has 5 study locations across California, Colorado, Georgia, Rhode Island, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
RECRUITING · Phase 2
-
Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT
RECRUITING · Phase 2
-
Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
RECRUITING · Phase 2
-
Imaging Immune Activation in HIV by PET-MR
RECRUITING · Phase 2
-
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.